DK3512544T3 - Peptidforbindelser og terapeutiske anvendelser deraf - Google Patents

Peptidforbindelser og terapeutiske anvendelser deraf Download PDF

Info

Publication number
DK3512544T3
DK3512544T3 DK17771531.5T DK17771531T DK3512544T3 DK 3512544 T3 DK3512544 T3 DK 3512544T3 DK 17771531 T DK17771531 T DK 17771531T DK 3512544 T3 DK3512544 T3 DK 3512544T3
Authority
DK
Denmark
Prior art keywords
therapeutic uses
peptide compounds
peptide
compounds
therapeutic
Prior art date
Application number
DK17771531.5T
Other languages
English (en)
Inventor
Melanie Glossop
Christine Watson
Michael Westby
Original Assignee
Centauri Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1615560.8A external-priority patent/GB201615560D0/en
Priority claimed from GBGB1707076.4A external-priority patent/GB201707076D0/en
Application filed by Centauri Therapeutics Ltd filed Critical Centauri Therapeutics Ltd
Application granted granted Critical
Publication of DK3512544T3 publication Critical patent/DK3512544T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62Polymyxins; Related peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK17771531.5T 2016-09-13 2017-09-13 Peptidforbindelser og terapeutiske anvendelser deraf DK3512544T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1615560.8A GB201615560D0 (en) 2016-09-13 2016-09-13 Novel compounds and therapeutic uses thereof
GBGB1707076.4A GB201707076D0 (en) 2017-05-04 2017-05-04 Novel compounds and therapeutic uses thereof
PCT/GB2017/052699 WO2018051085A1 (en) 2016-09-13 2017-09-13 Novel compounds and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
DK3512544T3 true DK3512544T3 (da) 2021-02-01

Family

ID=59923474

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17771531.5T DK3512544T3 (da) 2016-09-13 2017-09-13 Peptidforbindelser og terapeutiske anvendelser deraf

Country Status (14)

Country Link
US (1) US11014966B2 (da)
EP (1) EP3512544B1 (da)
JP (2) JP7185622B2 (da)
KR (1) KR102544465B1 (da)
CN (1) CN110022896B (da)
AU (1) AU2017328896B2 (da)
BR (1) BR112019004877A2 (da)
CA (1) CA3036405A1 (da)
DK (1) DK3512544T3 (da)
ES (1) ES2854991T3 (da)
IL (1) IL265269B (da)
MX (1) MX2019002879A (da)
WO (1) WO2018051085A1 (da)
ZA (1) ZA201901422B (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201705686D0 (en) * 2017-04-07 2017-05-24 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB201804098D0 (en) * 2018-03-14 2018-04-25 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB201904534D0 (en) 2019-04-01 2019-05-15 Centauri Therapeutics Ltd Novel compounds an therapeutic uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645743B2 (en) 1999-12-22 2010-01-12 Altermune, Llc Chemically programmable immunity
CN1747970A (zh) * 2003-02-06 2006-03-15 三肽公司 抗原/抗体或配体/受体糖基化的特异性交换剂
ATE553113T1 (de) * 2003-02-28 2012-04-15 Agenus Inc Verwendung von lektinen zur förderung der oligomerisierung von glycoproteinen und antigenen molekülen
WO2010129666A1 (en) * 2009-05-05 2010-11-11 Altermune Technologies, Llc Chemically programmable immunity
EP2780357A1 (en) * 2011-11-18 2014-09-24 Novacta Biosystems Limited Polymyxin derivatives
JPWO2016104647A1 (ja) 2014-12-25 2017-10-05 国立大学法人大阪大学 糖鎖結合ワクチン抗原及び糖鎖導入剤
GB201517859D0 (en) * 2015-10-08 2015-11-25 Altermune Ltd Novel compounds and therapeutic uses thereof

Also Published As

Publication number Publication date
KR102544465B1 (ko) 2023-06-19
US20190248838A1 (en) 2019-08-15
IL265269B (en) 2022-04-01
WO2018051085A1 (en) 2018-03-22
CA3036405A1 (en) 2018-03-22
IL265269A (en) 2019-05-30
CN110022896A (zh) 2019-07-16
MX2019002879A (es) 2019-09-18
KR20190064592A (ko) 2019-06-10
EP3512544A1 (en) 2019-07-24
ES2854991T3 (es) 2021-09-23
AU2017328896B2 (en) 2024-07-25
ZA201901422B (en) 2020-11-25
JP2022184922A (ja) 2022-12-13
CN110022896B (zh) 2023-12-19
BR112019004877A2 (pt) 2019-06-11
AU2017328896A1 (en) 2019-04-04
EP3512544B1 (en) 2020-10-28
JP7185622B2 (ja) 2022-12-07
JP2019526614A (ja) 2019-09-19
US11014966B2 (en) 2021-05-25

Similar Documents

Publication Publication Date Title
DK3463465T3 (da) Exosomer omfattende terapeutiske polypeptider
DK3283106T3 (da) Terapeutiske antistoffer og anvendelser deraf
DK3448386T3 (da) Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf
DK3365368T3 (da) Tgfbeta1-bindende immunoglobuliner og anvendelse deraf
DK3452463T3 (da) Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
DK3412302T3 (da) Modificerede fgf-21-polypeptider og anvendelser deraf
DK3354282T3 (da) Glycan-terapeutiske midler og relaterede fremgangsmåder deraf
DK3268470T3 (da) Transposasepolypeptider og anvendelser deraf
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
DK3157552T3 (da) Syntac-polypeptider og anvendelser deraf
DK3723783T3 (da) Mitokondrie-målrettede peptider
DK3498292T3 (da) Uspa2-proteinkonstruktioner og anvendelser deraf
DK3102200T3 (da) Terapeutisk forbindelse og sammensætning
DK3290441T3 (da) Rgma-bindingsprotein og anvendelse deraf
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
DK3408265T3 (da) Terapeutiske forbindelser
DK3615502T3 (da) Terapeutiske forbindelser og fremgangsmåder
DK3560925T3 (da) Hidtil ukendt forbindelse og farmaceutisk acceptabelt salt deraf
DK3365321T3 (da) Solabegron-zwitterion og anvendelser deraf
ZA201902689B (en) Therapeutic protein
DK3194583T3 (da) Ikke-fucosyleret protein og fremgangsmåder dermed
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf
DK3388085T3 (da) Farmaceutisk sammensætning og anvendelser deraf
DK3229827T3 (da) Modificerede peptider og anvendelse deraf til behandling af kroniske inflammatoriske sygdomme
DK3512544T3 (da) Peptidforbindelser og terapeutiske anvendelser deraf